TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia
Cancer Medicine · 2023-02 · 12 (4) · 3952-3961
DOI: 10.1002/cam4.5196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 03.09.2022. Verfasst von Cunte Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
It is imperative to explore potential biomarkers for predicting clinical outcome and developing targeted therapies for T‐cell acute lymphoblastic leukemia (T‐ALL). This study aimed to investigate the mutation patterns of tumor necrosis factor‐alpha‐inducing protein 3 ( TNFAIP3 , also known as A20 ) and its role in the prognosis of T‐ALL patients.
Methods
Polymerase chain reaction (PCR) and Sanger sequencing data from T‐ALL ( n = 49, JNU) and targeted sequencing data from T‐ALL ( n = 54, NFH) in our clinical center and a publicly available dataset ( n = 121, PRJCA002270), were used to detect TNFAIP3 mutation.
Results
Three TNFAIP3 single nucleotide polymorphisms (SNPs; g.3033 C > T, g.3910 G > A, and g.3904 A > G) were detected in T‐ALL in the JNU dataset, and g.3033 C > T accounted for the highest proportion, reaching 60% (6/10). Interestingly, TNFAIP3 mutation mainly occurred in adults but not pediatric patients in all three datasets (JNU, NFH, and PRJCA002270). T‐ALL patients carrying a TNFAIP3 mutation were associated with a trend of poor overall survival (OS) ( p = 0.092). Moreover, TNFAIP3 mutation was also an independent factor for OS for T‐ALL patients ( p = 0.008). Further subgroup analysis suggested that TNFAIP3 mutation predicted poor OS for T‐ALL patients who underwent chemotherapy only ( p < 0.001), and it was positively correlated with high risk and early T‐cell precursor ALL (ETP‐ALL) in two independent validation datasets (NFH and PRJCA002270).
Conclusion
TNFAIP3 mutation mainly occurs in adult T‐ALL patients, and it was associated with adverse clinical outcomes for T‐ALL patients; thus, it might be a biomarker for prognostic stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China.
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Rheumatism and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, China.
- Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China.
- Department of Oncology, First Affiliated Hospital, Jinan University, Guangzhou, China.
ORCID-Profile: Cunte Chen, Chengwu Zeng, Yangqiu Li
Zitieren
APA
Chen, C., Zhou, L., Zhu, L., Luo, G., Wang, L., Zeng, C., Zhou, H., & Li, Y. (2023). TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia. Cancer Medicine, 12(4), 3952-3961. https://doi.org/10.1002/cam4.5196
Vancouver
Chen C, Zhou L, Zhu L, Luo G, Wang L, Zeng C, et al. TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia. Cancer Medicine. 2023;12(4):3952-3961. doi:10.1002/cam4.5196
BibTeX
@article{Chen2023,
author = {Chen, Cunte and Zhou, Lingling and Zhu, Lihua and Luo, Gengxin and Wang, Liang and Zeng, Chengwu and Zhou, Hongsheng and Li, Yangqiu},
title = {TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {3952--3961},
doi = {10.1002/cam4.5196}
}
EUVIMED